UNCY Company Profile and Key Details

UNCY has shown sold momentum, gaining 12.1% over the past week and 39.7% over the past quarter, though year-to-date performance is up 14.04%. Short-term trend indicators are bearishly aligned (SMA20 5.81%, SMA50 9.32%, SMA200 26.43%). The stock’s 14-day RSI is 56.26 (neutral), while the ATR of 0.41 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -37.82% below its high and over 84.37% above its low. Average 10-day trading volume of 718.08 thousand shares is below the 3-month average of 1.47 million, indicating normal recent market interest.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) closed at $5.12 USD, gaining $0.09 (1.79%) from the previous close of $5.03. The stock is currently mid-range between its 52-week high and low $3.71 and $8.74. With a market capitalization of about $136.70 million, Unicycive Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.78). Key stats such as the average daily volume over the past year has been around 1.50 million shares, volume is running light vs its 52-week average. Headquartered in Mountain View, CA, Unicycive Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Shalabh K. Gupta, the company employs approximately 21 people and listed since July 12, 2021. Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases.

Unicycive Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.83. This means the shares are trading above this model’s fair value.

Unicycive Therapeutics, Inc. has 27.39 million shares outstanding. The public float is 27.23 million shares, elevated short interest at 16.18% of float. This equals 4.33 million shares. The short ratio is 1.98 days. Institutional investors hold 43.23% of the float. Insiders own 2.26%.

Unicycive Therapeutics, Inc. generated EPS of -$3.25 over the past year. Five-year average earnings growth is -31.8%. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.47. Next year's EPS is expected at $66.05. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $13.00. The high target offers 876.56% upside. The low target suggests 153.91% downside. The mean target is $25.30. This offers 394.14% upside. Unicycive Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 12, 2026, missed forecasts by -87.26%. The prior quarter beat by 17.68%. Over the last six quarters, Apple has recorded several small beats. These include 100.0% in March 31, 2025.

Unicycive Therapeutics, Inc. trades at a P/E ratio of -3.04, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.57 suggesting the stock is closer to book value. The P/FCF stands at -4.88, also below market averages.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) shares are up 14.04% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Unicycive Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.04. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $11.74, suggesting 129.3% upside. Our AI forecast model points to short-term weakness (-1.17% over two weeks), a medium-term rise (41.6% over three months), and a longer-term gain (125.2% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Unicycive Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.17%, with price expected at $5.06 by September 22, 2026, within a range of $4.78 to $5.33 3-Month Outlook: Projected rise of 41.6%, reaching $7.25 by December 07, 2026, with a range of $7.05 to $7.40. 1-Year Outlook: Projected gain of 125.2%, with price at $11.53 by September 08, 2027, within a range of $2.78 to $17.18.